Enhancements    

Pharmaceutical Compositions Which Inhibit FKBP52-Mediated Regulation of Androgen Receptor Function and Methods of Using Same

Pharmaceutical Compositions Which Inhibit FKBP52-Mediated Regulation of Androgen Receptor Function and Methods of Using Same
Inventors: Marc Cox, Heather Balsiger, Aki Iwai, Yeong Kim, Jane Neckers, Leonard Neckers, Yangmin Ning, Johanny Torros de Leon
Patent No. 8,859,207

Description:
This patent consists of pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor.

Abstract:
Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.

Issue Date: 10/14/2014
Application Date: 05/04/2012
Post Date: 03/02/2018

UTEP Docket No: 2009-014